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Simple Summary: Management of gastric and gastroesophageal junction (GEJ) adenocarcinoma
remains challenging, because of the heterogeneity in tumor biology within the upper gastrointestinal
tract. This manuscript is the product of a formal consensus process conducted in three Delphi
rounds and a consensus meeting by the GAIN (GAstric cancer Italian Network) group. The goal
of this document is to present a synthesis of available evidence and, where this is lacking, to
provide expert opinion directed at prevention, diagnosis, and proper management of gastric and GEJ
adenocarcinoma, and in particular aspects of practical management not fully supported by guidelines.
Abstract: Background: Management of gastric and gastroesophageal junction (GEJ) adenocarcinoma
remains challenging, because of the heterogeneity in tumor biology within the upper gastrointestinal
tract. Daily clinical practice is full of grey areas regarding the complexity of diagnostic, staging, and
therapeutic procedures. The aim of this paper is to provide a guide for clinicians facing challenging
situations in routine practice, taking a multidisciplinary consensus approach based on available
literature. Methods: The GAIN (GAstric cancer Italian Network) group was established with the aims
of reviewing literature evidence, discussing key issues in prevention, diagnosis, and management
of gastric and GEJ adenocarcinoma, and offering a summary of statements. A Delphi consensus
method was used to obtain opinions from the expert panel of specialists. Results: Forty-nine clinical
questions were identified in six areas of interest: role of multidisciplinary team; risk factors; diagnosis;
management of early gastric cancer and multimodal approach to localized gastric cancer; treatment
of elderly patients with locally advanced resectable disease; and treatment of locally advanced
and metastatic cancer. Conclusions: The statements presented may guide clinicians in practical
management of this disease.
Keywords: gastric cancer; GEJ adenocarcinoma; recommendations; treatment; diagnosis
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1. Introduction
Gastric cancer represents a significant health problem—it is the third leading cause
of cancer death worldwide, although incidence varies widely [1]. Management of gastric
and gastroesophageal junction (GEJ) adenocarcinoma remains challenging, because of the
heterogeneity of tumor biology within the upper gastrointestinal tract; the complexity of
diagnostic, staging, and therapeutic procedures; and differences in treatment algorithms [2].
As a consequence, a multidisciplinary approach has long been advocated as crucial to
personalize management [3,4].
Although several authoritative guidelines are available, daily practice is full of uncer-
tainties, as high-quality evidence and conclusive studies are lacking. The GAIN (GAstric
cancer Italian Network) group was established with the aim of filling this gap between
evidence and practice. Experts in the field selected the major open questions in the man-
agement of gastric and GEJ adenocarcinoma, reviewed literature evidence, discussed key
issues in prevention, diagnosis, and management, and provided recommendations to be
used in clinical practice.
2. Methods
This multidisciplinary consensus was developed by the GAIN group, comprising 19
oncologists, five surgical oncologists, one gastroenterologist, one pathologist, one nuclear
doctor, one radiologist, one radiation oncologist, one nutritionist, and a patient representa-
tive. Clinical centers were chosen according to their expertise in gastric cancer management
across Italy.
A Delphi consensus method was used to obtain opinions from the panel. Two prepara-
tory meetings, three Delphi rounds, and a final consensus conference took place between
May 2019 and March 2020. In the preparatory meetings, decisions were made on the
final scope and structure of the project, composition of the expert panel, methods, and
topics, including relevant clinical questions that the consensus should address. Forty-nine
clinical questions were identified in six areas of interest: role of multidisciplinary team;
risk factors; diagnosis; management of early gastric cancer and multimodal approach to
localized gastric cancer; treatment of elderly patients with locally advanced resectable
disease; treatment of locally advanced and metastatic cancer.
A group of experts (three oncologists and two surgical oncologists) reviewed the
literature to answer the clinical questions identified and proposed a draft of statements
with supporting evidence for each topic. Key issues were discussed at a second face-to-
face meeting in July 2019, after which a comprehensive document was circulated to the
expanded group of experts. Each expert was asked to comment and suggest modifications
to the draft statements through a Delphi method. Throughout Delphi rounds, participants
were asked to rate their agreement with each statement with a three-point Likert scale:
disagree, abstain, agree; consensus was defined as >70% “agree” with <15% “disagree”.
Statements with levels of agreement <70% were re-worded or were clarified with additional
words in subsequent Delphi rounds, in response to respondent’s comments. If no final
agreement was reached after the consensus conference, those statements were eliminated
(statements included: 74 out of 82 initial statements). These suggestions were made
available to the other experts in a series of web-based discussion rounds (three online
rounds) for further discussion and definitive approval. A final consensus online meeting
was held on 26 March 2020.
3. Results
3.1. Role of Multidisciplinary Team
Unanswered questions: What is the impact of multidisciplinary discussion on thera-
peutic decision-making in patients with gastroesophageal cancer? Which specialists should
be involved in the multidisciplinary team (MDT)?
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3.1.1. Statements
All newly diagnosed gastroesophageal cancer cases must be discussed within the MDT
and regularly reviewed as this is associated with improvements in overall management
(from diagnosis to staging and treatment). The MDT should comprise an abdominal sur-
geon, radiation oncologist, medical oncologist, pathologist, radiologist, gastroenterologist,
and a specialist in clinical nutrition.
3.1.2. Sources of Evidence
Management of gastroesophageal cancers requires complex clinical decision-making.
MDT involvement is required to ensure timely and appropriate care by different specialists.
Several studies confirm that roundtable discussions within MDTs are associated with
improvements in staging/diagnosis, survival improvement, adherence to international
guidelines, and promoting the execution of multimodal treatments in many cases [5–8].
Usually, patients with gastroesophageal cancer have weight loss at diagnosis—an
indicator of malnutrition or risk for developing malnutrition. Malnutrition and sarcopenia
(particularly reduced lean body mass) have prognostic bearing on outcomes at all disease
stages [9,10]. Involvement of dedicated nutritional specialists increases the chance of
successful outcome. The nutrition team should include at least one physician (internist,
gastroenterologist, endocrinologist, or nutritionist) and a dietitian [11,12].
3.2. Risk Factors
3.2.1. Precancerous Conditions: Chronic Gastritis with Intestinal-Type Metaplasia, Chronic
Atrophic Gastritis
Unanswered questions: How are higher-risk populations defined? Which diagnostic
tools and staging procedures can be recommended in suspected precancerous conditions?
How is appropriate follow-up of precancerous conditions chosen?
Statements
(1) An esophagogastroduodenoscopy (EGDS) should be performed on all patients pre-
senting with new onset dyspeptic symptoms, regardless of the presence of gastroe-
sophageal reflux or other risk factors such as active smoking or H. pylori positivity.
Population screening is recommended in Asian countries but there is no evidence to
support it in Western populations.
(2) Early identification of patients with chronic atrophic gastritis and intestinal meta-
plasia (including Barrett) is fundamental to endoscopic staging by the updated Syd-
ney system, with an accurate assessment of the degree of atrophy/metaplasia with
OLGA (Operative Link on Gastritis Assessment) and OLGIM (Operative Link on
Gastritis/Intestinal-Metaplasia Assessment) classification systems.
(3) Endoscopic surveillance of precancerous lesions must be guided by both severity
of the histologic finding and the extent and association of other risk factors such
as familial gastric neoplasia, autoimmune gastritis, Barrett, and non-eradication
of H. pylori infection. Endoscopic surveillance is recommended every 3 years in
patients with intestinal metaplasia limited to the antrum or gastric body, mainly for
patients with familial gastric neoplasia, autoimmune gastritis, or non-eradication of
H. pylori infection. In patients with chronic atrophic gastritis and/or diffuse intestinal
metaplasia, endoscopic follow-up every 1–2 years is recommended.
Sources of Evidence
Precancerous conditions such as chronic atrophic gastritis and intestinal metaplasia
(including Barrett) represent histologic findings in about one-third of patients on EGDS
for dyspeptic symptoms or gastroesophageal reflux [13]. The recommended endoscopic
sampling protocol is the updated Sydney system, including five biopsies: two from antrum,
two from corpus, and one from the incisura angularis, with additional sampling of suspi-
cious areas.
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The degree of atrophy and metaplasia should be assessed by OLGA and OLGIM
staging, to identify the risk of neoplasia: patients with stage III and IV are at highest
risk of carcinogenesis [14,15]. Major risk factors are age >60, smoking history, and H.
pylori infection. The American College of Gastroenterology/Canadian Association of
Gastroenterology guidelines on dyspepsia management recommend an endoscopic baseline
assessment in all patients >60 years with new-onset dyspepsia, especially in those with
other risk factors (family history of gastric neoplasia or living in high-risk areas) [16]. A
correlation between H. pylori infection and chronic atrophic gastritis has been confirmed in
two meta-analyses, thus highlighting the significant incidence of chronic atrophic gastritis
in serologically positive populations [17–19]. In a Korean study, patients achieving H.
pylori eradication showed a significant regression of previous precancerous conditions [20].
Population screening is recommended in Asian countries, where screening campaigns
from age 50, with an endoscopic evaluation or a barium study of the digestive tract every
2 years, have shown significant benefit in early diagnosis and reduced mortality [21,22].
Conversely, in Western countries, population screening is not recommended [23].
Once a precancerous lesion is identified, correct endoscopic follow-up is essential
(Table 1), with the timing between endoscopic evaluations based on risk of neoplastic evo-
lution. In patients with chronic atrophic gastritis and intestinal metaplasia, the annual risk
for developing gastric neoplasia is 0.1% and 0.25%, respectively; the risk is increased in pa-
tients with extensive preneoplastic localization and familial gastric cancers [24,25]. Patients
with limited antral intestinal metaplasia therefore require scheduled follow-up in specific
conditions such as familial gastric cancers, autoimmune gastritis, or non-eradication of H.
pylori infection [14]. Endoscopic follow-up is essential in patients with chronic atrophic
gastritis and/or intestinal metaplasia extended over the antrum, and timing between endo-
scopic monitoring should be based on risk factors (familial gastric cancers, autoimmune
gastritis, failure to eradicate H. pylori infection). In patients with dysplasia without suspi-
cious lesions, an endoscopic evaluation at a tertiary center should be performed initially,
with a possible review by expert pathologists to confirm the previous diagnosis and guide
the correct endoscopic follow-up [26]. If evident lesions are absent, even at subsequent
endoscopic evaluations, a new EGDS must be performed within 6 months in high-grade
dysplasia and within 1 year in low-grade dysplasia.






limited to the gastric
antrum or body
Every 3 years
Endoscopic surveillance with EGDS at
least every 3 years must be considered
mainly for patients with familial gastric
neoplasia, autoimmune gastritis, or




Every 1–2 years Scheduled endoscopic follow-up withcontrols 1–2 years is recommended.
Gastric dysplasia
Within 6 months for high-grade
dysplasia and within 1 year for
low-grade dysplasia.
In patients with dysplasia without
suspicious lesions, first, an endoscopic
evaluation at a third-level center should
be performed, and possibly a review by
expert pathologists to confirm the
previous diagnosis and guide endoscopic
follow-up. In the absence of evident
lesions, even at the subsequent endoscopic
evaluation, a new EGDS must be
performed within 6 months for high-grade
dysplasia and within 1 year for low-grade
dysplasia.
EGDS, esophagogastroduodenoscopy.
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3.2.2. Family History of Gastric Cancer and Hereditary Gastric Cancer (HDGC and Other
Syndromes)
Unanswered question: How are patients at high risk of familial or hereditary gastric
cancer identified? Who should get genetic testing?
Statements
(1) Genetic testing is recommended if: there is family history of ≥2 cases of gastric cancer
at any age, in first- or second-degree relatives, with ≥1 diffuse histology; a diagnosis
of diffuse gastric cancer before age 40 years; or in families with both diffuse gastric
cancer and lobular breast cancer with a case identified before age 50 years.
(2) Genetic testing should also be considered for all patients with a diagnosis of gastric
neoplasia and a family history compatible with Lynch syndrome, FAP, Peutz–Jeghers,
Li–Fraumeni, juvenile polyposis, hereditary breast and ovarian cancer syndrome
(germline mutations in BRCA1 or BRCA2).
Sources of Evidence
Although most gastric cancers are sporadic, a familial predisposition occurs in approx-
imately 10% of cases. Hereditary gastric cancers account for 1–3% of all cases and include at
least three main syndromes: hereditary diffuse gastric cancer (HDGC; with a genetic basis
in approximately 40% of HDGC cases); gastric adenocarcinoma and proximal polyposis of
the stomach (GAPPS); and familial intestinal gastric carcinoma (FIGC) [27]. Gastric cancer
has also been identified in several other hereditary tumor syndromes, including Lynch
syndrome, Li–Fraumeni syndrome, familial adenomatous polyposis (FAP), Peutz–Jeghers
syndrome, juvenile polyposis, and hereditary breast and ovarian cancer syndrome [27].
Scheduled endoscopic follow-up of these patients is necessary and should be performed at
reference centers.
When deciding whether to propose genetic testing, the familial history of gastric
cancer, histologic classification, and age of disease onset must be considered. International
Gastric Cancer Linkage Consortium criteria to identify patients with suspected HDGC
syndrome for genetic testing are: (1) ≥2 cases of gastric cancer at any age in first- or second-
degree relatives, with ≥1 diffuse histology; (2) diagnosis of diffuse gastric cancer before age
40 years; (3) families with both diffuse gastric cancer and lobular breast cancer with a case
identified before age 50 years. Genetic testing should also be considered for patients with
bilateral lobular breast cancer before age 50 years or who have ≥2 relatives with lobular
breast cancer before 50 years, a personal or family history of diffuse gastric cancer and cleft
palate/lip or in situ signet ring cell (SRC) carcinoma and/or pagetoid spread of SRCs [27].
Only families with HDGC criteria are tested for CDH1 mutations; endoscopic surveillance
is offered periodically to people at higher risk in non-HDGC families [28]. All patients with
HDGC should ideally receive total gastrectomy, as there is endoscopic follow-up failure
in >50% of patients and a >80% risk for developing gastric neoplasia during the course
of life [29]. Patients should also be followed up annually with bilateral breast magnetic
resonance imaging (MRI) and colonoscopy every 3–5 years [30].
The genetic alterations underlying GAPPS and FIGC are unknown. Clinical criteria to
identify those at higher risk of GAPPS are: (1) gastric polyposis restricted to corpus and
fundus of the stomach without evidence of duodenal and colorectal polyposis; (2) >100
polyps in the proximal stomach or >30 polyps in a first-degree relative; (3) predominantly
fundic gland polyps, some harboring dysplastic regions; (4) an autosomal dominant pattern
of inheritance [31].
A diagnosis of FIGC should be considered for a family history of intestinal-type gastric
cancer without gastric polyposis. In countries with high incidence rates of gastric cancer the
diagnostic criteria for FIGC are close to Amsterdam criteria for Lynch syndrome, whereas
in countries with lower incidence rates of gastric cancer, FIGC can be hypothesized if ≥2
first- or second-degree relatives are affected by intestinal-type gastric cancer, one before
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age 50 years, or if >3 relatives are affected by intestinal-type gastric cancer, regardless of
age [32].
3.3. Diagnostic and Staging Work-Up
3.3.1. Pathologic Evaluation: Minimum Requirements for Diagnosis and Staging of
Gastric Cancer
Unanswered questions: What is the minimum biopsy set required for histopathologic
diagnosis and staging of gastric cancer? What are the minimum molecular requirements
of newly diagnosed gastric cancer? What is the minimum biopsy set for metastatic tissue
sampling? What must be reported in an ideal histopathologic report?
Statements
1. A histopathologic diagnosis on primary tumor requires at least 6 biopsy samples
(optimal 6–8 because of intratumoral heterogeneity).
2. The biopsy specimen report should contain histotype according to WHO classifi-
cation, expressing the presence and possible percentage of SRC component, Lau-
ren classification, and grading. The surgical anatomopathologic report should con-
tain: macroscopic description of the lesions and sites (primitive/lymph nodes/any
other samples), microscopic description including WHO classification, Lauren clas-
sification, grading, staging according to the most up-to-date TNM (Tumor-Nodes-
Metastasis) version, margin status, lymphovascular and perineural invasion, tumor
regression grading (TRG) according to Becker or Mandard after neoadjuvant treat-
ments. Metastatic LNFs (lymph nodes)/total LNFs for every lymph node station
should be identified by the surgeon, or at least perigastric lymph nodes (stations 1–7)
should be distinguished from extraperigastric lymph nodes (stations 8–12 and 12–16).
3. Microsatellite instability (MSI) should be reported for both operable and metastatic
disease, HER2-status assessment is mandatory in metastatic disease and could be
reported for localized disease. HER2 status should be determined by immunohis-
tochemistry (IHC) and/or FISH (fluorescence in-situ hybridization) in all patients
with metastatic cancer before first-line chemotherapy. HER2 status should prefer-
ably be determined on metastatic localization (if a result is not already available) or
surgical sample, because of intratumoral heterogeneity, but can also be performed
on gastric biopsy, in which case at least five samples must be evaluated for a correct
determination.
4. Determining PD-L1 expression is not yet mandatory but could be in the future
if immunotherapy approval processes require combined positive score (CPS) for
prescriptive purposes.
5. The panel recognizes that NTRK (neurotrophic receptor tyrosine kinase) 1, 2, or 3
genes fusion may be targeted by EMA-approved agnostic drugs such as larotrec-
tinib or entrectinib. These alterations may be identified by immunohistochemistry
or nucleic acid-based techniques. However, incidence of gene fusion is low (<1%)
in gastroesophageal cancer [33–36], particularly among Caucasian patients [37], and
diagnostic techniques may be not routinely available at all institutions. Therefore,
screening of NTRK gene fusion cannot be universally recommended, but is encour-
aged for pretreated patients without validated therapeutic alternatives [38–42].
Sources of Evidence
Considering the intratumoral heterogeneity of gastric cancer, ≥4 biopsies should be
performed both on primitive lesion and surrounding area; to achieve a sensitivity of close
to 100% 6–8 biopsies are required [34]. The anatomopathologic report should therefore
contain the WHO classification with SRC component, Lauren classification, and grading.
Correct pathologic staging of surgical specimens is essential, according to the most up-to-
date version of the TNM system, as well as reporting the degree of TRG after neoadjuvant
treatment. Mandard and Becker systems are useful for prognosis in gastric cancer; however,
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the prognostic role of TRG as an indicator of response and therefore a surrogate marker of
survival is still controversial [36]. A post-hoc analysis of the MAGIC study highlighted
that only lymph node status is a significant prognostic factor (overall survival [OS]: hazard
ratio [HR] 3.36; 95% CI, 1.70–6.63; p < 0.001) [36].
Other globally validated prognostic factors are margin status (R0/R1/R2), histotype,
WHO, and Lauren classification subtype (including the percentage of SRCs if present) [35].
The presence of a diffuse histotype (Lauren classification) and of SRC component are
recognized prognostic factors, whereas their predictive role is controversial and still being
evaluated [35].
In the metastatic setting, evaluating HER2 status is mandatory. Overexpression
of HER2 is frequent in proximal cancer (24–32% GEJ; 9.5–18% distal stomach) with an
intestinal subtype (16–34% intestinal; 6–7% diffuse) [33,37].
HER2 status is the only validated predictive molecular biomarker in gastric can-
cer [43,44]. HER2 status must be determined quantitatively by IHC, with equivocal cases
confirmed by in-situ hybridization techniques (FISH recommended) [44]. HER2-positivity
is defined by the presence of a 3+ or 2+ IHC score with positive FISH, whereas HER2-
negative status is characterized by 0, 1+, or 2+ IHC and negative FISH [44]. As part of this
determination, the sample and techniques used are fundamental: times and methods of
fixation are important so that the analysis is not invalidated (criteria are different for biopsy
vs. operation samples), the pathologist must have experience in IHC evaluation, and
there should be >6 biopsy specimens because of intratumoral heterogeneity [45,46]. This
heterogeneity is amplified in metastatic tissue: a diagnostic biopsy should be performed at
the most accessible metastatic site with a new biopsy considered in the event of disease
progression for new molecular characterization of the neoplasm [47].
HER2-positive tumors can present primary resistance to target treatments (trastuzumab)
or secondary resistance during anti-HER2 therapy owing to the appearance of molecular
escape mechanisms, including expression loss of the receptor itself [48,49]. The devel-
opment during the past decade of multiple molecular classifications for stomach cancer
(specifically, The Cancer Genome Atlas [TCGA] and Asian Cancer Research Group) has
identified multiple biomolecular prognostic and predictive markers, such as PD-L1 expres-
sion, microsatellite instability (MSI), tumor mutational burden, and Epstein–Barr virus
(EBV) status [50]: the anatomopathologic report, particularly in metastatic setting, might
contain this information.
Incidence of MSI-high cancers varies from 8.2% to 37% in patients with gastric can-
cer [51]. The prognostic and predictive role of MSI in gastric cancer is still under investiga-
tion but in March 2017, the FDA approved the use of pembrolizumab in all patients with
metastatic or unresectable tumors with MSI or mismatch repair system protein deficiency
after progression on previous chemotherapy and without any additional therapeutic al-
ternatives. Therefore, the determination of microsatellite status should be carried out in
all patients progressing after two previous therapeutic lines for metastatic gastric cancer:
this determination could also play a role in future perioperative settings. PD-L1 expres-
sion seems to be a predictive marker for selecting patients with metastatic gastric cancer
and greater benefit from immunotherapy after ≥2 treatment lines (KEYNOTE-059) or in
first-line HER2-negative tumors (KEYNOTE-062) [52,53]. CPS should be used to determine
PD-L1, as this is the method used in clinical trials [54].
3.4. Preoperative Staging
3.4.1. The Role of Endoscopic Ultrasound
Unanswered question: What is the role of eco-endoscopy in preoperative staging and
response assessment in patients being evaluated for perioperative treatment?
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Statements
(1) Endoscopic ultrasound (EUS) is the most accurate staging method for defining T pa-
rameters; its use is therefore recommended when this impacts the treatment approach
(endoscopic resection, upfront surgery, perioperative treatment) (Table 2).
(2) The usefulness of EUS in evaluating response after neoadjuvant chemotherapy or
chemoradiotherapy appears limited, so it should not be used for restaging outside
clinical trials (Table 2).
Sources of Evidence
A Cochrane review confirmed good sensitivity (86%) and specificity (90%) for EUS to
discriminate between cT1/2 and cT3-cT4 forms, with greater diagnostic accuracy compared
with CT scan and MRI [55]. Similar sensitivity and specificity values are obtained for EUS
when discriminating between cT1 and cT2; however, specificity decreases when discrimi-
nating between cT1a and cT1b. For lymph node positivity, sensitivity and specificity of
EUS are 67% and 83%, respectively.
The role of EUS in assessing response to preoperative treatment is highly controversial:
the accuracy of EUS in evaluating T and N parameters is reduced, with poor diagnostic
performance, particularly in patients treated with chemoradiotherapy [56,57].
3.4.2. The Role of FDG PET/CT
Unanswered question: What is the role of FDG PET/CT in locally advanced disease
staging of gastroesophageal cancer (particularly evaluating occult disease: retroperitoneal
lymph nodes, peritoneal carcinosis, bone metastases)? Is there any predictive role for FDG
PET/CT after neoadjuvant treatment?
Statements
(1) Consider PET/CT with [18] F-FDG (fluorodeoxyglucose positron emission tomog-
raphy/computed tomography) in addition to radiologic imaging in patients with
locally advanced gastric cancer when there is no evidence of metastatic disease and
in case of suspected secondary lesions at CT scan (Table 2).
(2) FDG PET/CT during treatment or after the end of treatment is useful for identify-
ing patients without any benefit from neoadjuvant treatment; however, this role is
marginal outside clinical trials.
Sources of Evidence
FDG PET/CT improves diagnostic accuracy compared with CT alone, particularly for
identifying occult metastases (retroperitoneal lymph node involvement, bone metastases,
and peritoneal carcinosis) to prevent unnecessary surgery [58,59]. The greatest clinical
impact of FDG PET/CT is in patients with intestinal or mixed histotype according to
Lauren classification, whereas in those with diffuse histotype sensitivity is limited [60,61].
Another possible role of FDG PET/CT is the early evaluation of metabolic response to
neoadjuvant treatment (14 days after the first cycle of chemotherapy): metabolic response
does not predict pathologic response but identifies a group of patients without any benefit
from preoperative treatment who may proceed immediately to resection or receive modified
multimodal treatment [62–64].
3.4.3. Role of Laparoscopic Surgery
Unanswered questions: When should staging laparoscopy and peritoneal cytology
be performed? Is there any role for laparoscopic re-evaluation after neoadjuvant treatment?
Statements
(1) Staging laparoscopy with peritoneal cytology analysis at diagnosis should be consid-
ered in all patients at risk for undiagnosed peritoneal disease (cT3/4 and/or cN+),
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after collegial discussion, especially in those with suspected peritoneal carcinosis and
neoadjuvant therapy candidates, to define the correct therapeutic procedure.
(2) Exploratory/staging laparotomy is not recommended.
Sources of Evidence
About 10–20% of locally advanced gastric cancers have occult peritoneal spreading
undiagnosed by common imaging tests and the risk is increased among patients with
higher clinical T and N stages as well as in specific histologic subsets (such as diffuse-type
gastric carcinoma) [65]. Staging laparoscopy is a low-cost procedure with an excellent
sensitivity and specificity in peritoneal disease diagnosis [66]. However, the rate of positive
cytology in the absence of clinically evident peritoneal disease varies (10–40%) [67,68],
and although positive cytology is considered as stage IV disease, the outcome of these
patients is different from those with clinically evident peritoneal localizations [69]. In
neoadjuvant settings, negative peritoneal cytology after chemotherapy is a prognostic
rather than predictive factor, and occult peritoneal progression occurs in some cases [69,70].
Table 2. Multimodal approach in assessment of response during treatment.
Exam Timing Statement
CT scan Diagnosis CT scan is essential in gastric cancer staging
Echoendoscopy Diagnosis
EUS is the most accurate staging method for
definition of T parameter; its execution is
therefore recommended when this impacts the
treatment approach (endoscopic resection,
upfront surgery, perioperative treatment).
FDG PET/CT Diagnosis
Consider FDG PET/CT with 18F-FDG in
addition to radiologic imaging in patients with
locally advanced gastric cancer when there is
no evidence of metastatic disease and in case
of suspected secondary lesions at CT scan.
CT scan Response to neoadjuvanttreatment
CT scan is the gold standard in evaluating the
response after neoadjuvant chemotherapy.
Echoendoscopy Response to neoadjuvanttreatment
The usefulness of EUS in evaluating the
response after neoadjuvant chemotherapy or
chemoradiotherapy appears limited and so it
should not be used as restaging method
outside clinical trials.
FDG PET/CT Response to neoadjuvanttreatment
FDG PET/CT during treatment or after the
end of treatment should be useful to identify
patients without any benefit from neoadjuvant
treatment; however, this role is marginal
outside clinical trials.
CT scan Metastatic
Imaging for disease assessment should be
preferentially performed every 2 months with
metastatic disease and should be accompanied
by detailed and close monitoring of patient
clinical conditions.
EUS, endoscopic ultrasound; FDG PET/CT, fluorodeoxyglucose positron emission tomography/computed
tomography.
3.4.4. Role of Nutritional Support during Early Phases of Disease
Unanswered question: What is nutrition screening? What is nutrition counseling?
When should enteral nutrition be used?
Statements
(1) Validated screening tests for malnutrition should be used in all patients with gastric
cancer before any anti-cancer treatment. For pathologic screening tests, the nutritional
team must be involved in setting up an intervention.
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(2) Nutritional counseling should be the first intervention in pathologic nutritional
screening. This aims to maintain adequate weight and quality of life (QoL) dur-
ing chemotherapy.
(3) Enteral nutrition support in patients treated with radical-intent gastrectomy should
be considered in (neo-)adjuvant settings. After surgery, enteral nutrition can be
performed through jejunostomy and continued at home.
Sources of Evidence
Nutrition screening is the first step in identifying patients who are at risk for nutri-
tion problems or with undetected malnutrition [71]. Several validated screenings MUST
(malnutrition universal screening tool), NRS (nutritional risk screening) are available that
consider weight loss, body mass index, and feeding limitation [72,73]. For pathologic
screening, involvement of the nutritional team is important to perform a more detailed
assessment of the state of nutrition and define the degree of malnutrition according to
recent European Society of Clinical Nutrition and Metabolism guidelines [73]. The first
level of intervention is nutrition counseling by an expert dietician (Table 3). Nutritional
advice is a useful tool for optimizing nutrition per os, increasing calories and protein intake,
promoting an adequate body weight, and improving patients’ QoL [74,75].
Perioperative nutritional support is essential in candidates for surgery and possible
adjuvant CT, particularly for malnourished patients [76,77]. Enteral nutrition (for example,
by jejunostomy feeding tube) has been shown to reduce morbidity and duration of hospi-
talization compared with parenteral support and can be easily continued at home, thus
promoting adequate nutritional status 3–6 months post-surgery, with better tolerance of
adjuvant chemotherapy [78].
Table 3. Nutritional support: how and when?
Nutritional Action Stage of Disease Statement
Role of nutrition experts All
The presence of a clinical nutrition specialist in the
MDT allows the possibility of performing
multimodal treatments. The nutrition team should
include at least one physician (internist,
gastroenterologist, endocrinologist, or nutritionist)
and a dietitian.
Nutritional screening All
Validated screening test to assess the presence of
malnutrition should be provided to all patients
with gastric cancer before any anticancer treatment.
For pathologic screening, the nutritional team
must be involved in setting up an intervention.
Nutritional counseling All
For pathologic nutritional screening, nutritional
counseling should be the first intervention.
Nutritional counseling aims to maintain adequate
weight and QoL during chemotherapy.
Enteral nutrition Localized disease
Enteral nutrition support in patients treated with
radical gastrectomy should be considered in
(neo-)adjuvant settings.
Parenteral nutrition Metastatic
Parenteral nutrition is effective in improving
nutritional status and QoL, and in some selected
patients with advanced gastric cancer. It is a valid




Nutritional status assessment must be performed
upfront in all patients who are candidates for
systemic therapies. The need for nutritional
support and the program for such support should
be established by a dedicated nutrition expert.
QoL, quality of life.
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3.5. Management of Early Gastric Cancer and Multimodal Approach to Localized Gastric Cancer
3.5.1. Endoscopic Treatment
Unanswered questions: What criteria should be used to choose between endoscopic
resection and gastrectomy? How should endoscopic follow-up after local dissection be man-
aged?
Statements
(1) Endoscopic treatment is only reliable in early gastric cancers with Lauren intestinal
histotype, <2 cm, well-differentiated, non-ulcerated, involving only the mucosa (T1a),
and without clinical suspected lymph node involvement. Endoscopic resection can
only be considered curative when histologic examination of the sample after endo-
scopic resection confirms all the above criteria with negative margin status (en bloc
resection) in absence of vascular-lymphatic infiltration.
(2) Surgical treatment is the therapeutic option for all early gastric cancers that do not
meet the criteria described above, or when evaluation of the specimen does not
confirm the radicality of the endoscopic resection.
(3) After endoscopic resection of early gastric cancers, endoscopic follow-up after 3 months,
6 months, 1 year, then annually for 5 years is indicated to exclude the presence of
locoregional recurrence.
Sources of Evidence
Endoscopic resection is technically feasible and effective in 81% of early gastric can-
cers. Long-term disease-free survival (DFS) and disease-specific survival are similar after
endoscopy and gastrectomy resection for early gastric cancers (in all groups >95%) [79].
However, risk of relapse is greater after endoscopy (risk ratio, 2.5; 95% CI, 1.3–4.8; p = 0.005);
metachronous gastric tumor incidence is 7–10% in these patients [80,81]. Endoscopic treat-
ment can be evaluated in patients with early gastric cancers ≤2 cm, without clinically
evident lymph node metastases [82–84] (Figure 1).
Past series from the East used EUS (in combination with conventional endoscopy
and computerized tomography) for the decision-making of gastric cancer patients who
were candidates for endoscopic resection or surgery [85]. This approach is undoubtedly of
importance, considering mini-invasive surgery as the alternative treatment for early lesions.
Surgical treatment is the preferable option for patients with lesions >2 cm, clinically
suspected lymph node metastases, ulcerated and undifferentiated lesions, diffuse histo-
type, or differentiated lesions but with submucosal invasion [86,87]. Chromoendoscopy
allowed the differential diagnosis between early and premalignant lesions with sensitivity,
specificity, and AUC greater than simple endoscopy: 0.90 (95% CI, 0.87–0.92), 0.82 (95% CI,
0.79–0.86), and 0.94, respectively [88].
Endoscopic follow-up (together with abdominal CT scan, chest x-ray, and laboratory
tests) should be performed at 3 months, 6 months, 1 year, then annually for 5 years after
endoscopic early gastric cancer resection [83,89].
3.5.2. Principles of Adequate Surgery
Unanswered question: What are the principles of effective surgery?
Statements
1. The extent of gastric resection depends on tumor location and the possibility of
achieving an adequate free proximal margin.
2. D2 dissection is standard treatment in gastric cancer patients, with the exception of
early gastric tumors without nodal involvement.
Sources of Evidence
For gastric cancer treatment, surgery is always indicated with the exception of early
disease and metastatic tumors. The main role of good-quality oncologic surgery in gastric
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cancer management is widening the surgical dissection field to achieve a safe circum-
ferential resection margin including a nodal dissection larger than positive lymph node
stations [90]. This involves two key principles: primary tumor resection and lymphadenec-
tomy.
Primary Tumor Resection: Total gastrectomy can be avoided if a 5 cm-free resection
margin is achieved. However, distal gastrectomy still raises concerns about the radical
resection of distal SRC carcinoma due to the risk of underestimated linitis plastic [91]. The
extent of gastric resection depends on tumor location and the possibility of achieving an
adequate free proximal margin (possibly verified by frozen section examination of the
resection line) [91]. In particular with locally advanced disease (generally, after preopera-
tive treatment), splenectomy can be limited to selected tumors located along the greater
curvature of the stomach; multivisceral resection is indicated according to the judicious
balance between the option of a resection without any residual tumor and risks related to
the surgical procedure [92].
Open questions remain about the removal of the peritoneal surface of the omental
bursa (bursectomy) for tumors of the posterior gastric wall and total omentectomy. At
present, laparoscopic gastrectomy is only validated for distal tumors [93].
Lymphadenectomy: D2 dissection is standard treatment in gastric cancer patients, with
the exception of early gastric tumors without nodal involvement; removal of second-level
lymph nodes increases the number of retrieved nodes and the accuracy of N staging [94].
As far as it concerns resection margins, 3 issues are of concern for surgeons, including:
the minimum amount of macroscopic negative stomach required for a R0 resection, the
impact of an extended resection on patient outcomes/quality of life, and other biologic
factors including histology [67].
A recent systematic review including some 20,000 patients documented that positive
margins after surgery were associated with larger tumor size, T stage, nodal positivity,
higher stage, diffuse histology, higher Borrmann type, lymphatic vessel involvement, and
total gastrectomy [95].
All of these issues are more than prominent in the era of neoadjuvant treatments and
laparoscopic approaches. Still, however, discrepancies in the recommendations provided
by NCCN and the Japanese Gastric Cancer Treatment Guidelines based on T stages are
currently present.
3.5.3. Sequencing Surgery and Chemotherapy
Unanswered question: Perioperative or adjuvant chemotherapy?
Statements
(1) In patients with stage II or III gastric carcinoma, perioperative chemotherapy is the
standard of care. FLOT (5-fluorouracil [5-FU], oxaliplatin, and docetaxel) is first choice
in fit patients.
(2) Patient compliance to preoperative treatment is higher than postoperative treatment.
(3) Preoperative chemotherapy does not increase morbidity and early post-surgery mor-
tality: FLOT is not associated with greater risk for post-surgical complications or
mortality than ECF (epirubicin, cisplatin, and 5-FU) or ECX (epirubicin, cisplatin, and
capecitabine).
(4) After surgery without any preoperative treatment, an adjuvant therapy with fluo-
ropyrimidine and/or oxaliplatin is recommended.
(5) In the adjuvant setting after upfront surgery for pathologic stage II–III disease, the
combination of fluoropyrimidine and oxaliplatin should be considered the preferred
option in all patients with adequate recovery after resection.
(6) All patients undergoing surgery for stomach cancer should receive postoperative
treatment, regardless of prognostic factors and pathologic response.
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Sources of Evidence
Key evidence for the use of perioperative chemotherapy is provided by the MAGIC
and ACCORD 07/FFCD trials [96,97]. Data from these and 12 other studies that compared
perioperative treatment versus surgery alone were analyzed in a 2013 Cochrane meta-
analysis including 2422 patients with gastroesophageal neoplasm [98]. Perioperative
chemotherapy, regardless of the addition of radiotherapy, had a significant OS benefit
(HR = 0.81; 95% CI, 0.73–0.89) with an absolute death risk reduction of 9% [98].
Subsequently, three important prospective trials were published demonstrating:
(1) There is no difference in OS, but less toxicity, with two preoperative cycles of flu-
oropyrimidine and cisplatin compared with four preoperative cycles with ECX in
patients with esophageal and Siewert I-II GEJ cancers [99].
(2) There is no benefit from adding bevacizumab to perioperative ECX chemotherapy:
3-year overall survival 50.3% with chemotherapy versus 48.1% with addition of
bevacizumab [100].
(3) Pathologic regression grade/response (<pT1: 15% vs. 25%) and overall survival
(50 months vs. 35 months; HR = 0.77; 95% CI, 0.63-0.94; p = 0.012) benefit from
perioperative FLOT compared with the ECF/ECX combinations. OS at 2–3 and
5 years was 59%, 48%, and 36% with ECF/ECX compared with 68%, 57%, and
45% with FLOT [101]. Similar rates of post-surgical complications with FLOT and
ECF/ECX were reported (51% vs. 50%). Median duration of hospitalization was also
similar in the two arms (15 vs. 16 days), as were reoperation rates (10% vs. 11%), and
deaths within 30 days (2% vs. 3%) and within 90 days (5% vs. 8%).
The use of adjuvant chemotherapy in gastric carcinoma is supported by various meta-
analyses including one by the GASTRIC group, analyzing 3,838 patients enrolled in 17
randomized clinical trials, in which there was a relative reduction in mortality at 5 years of
18% (HR = 0.82; 95% CI, 0.76–0.90) compared with surgery alone with OS increased from
49.5% to 53% [102]. Polychemotherapy regimens are commonly used in Asian populations,
based on CLASSIC trial results comparing adjuvant Xelox (capecitabine + oxaliplatin) with
surgery alone: 5-year disease-free survival (DFS) increased from 53% to 68% (HR = 0.58;
95% CI, 0 47–072; p < 0.0001) and OS improved from 69% to 78% (HR = 0.66; 95% CI, 0
51-0 85; p = 0.0015) [103]. Similar evidence is lacking for European and US populations.
In JACCRO GC-07, addition of docetaxel to S1 alone (S1 is a fluoropyrimidine, similar
to 5-FU and capecitabine) in the adjuvant setting demonstrated significantly improved
3-year DFS post-surgery: S1 + docetaxel 66% versus S1 50% (HR = 0.63; 95% CI, 0.400–0.998;
p = 0.001) [104]. A network meta-analysis analyzed 5620 patients enrolled in 11 randomized
trials, demonstrating a significant survival benefit versus surgery alone from adjuvant treat-
ment with 5-FU + radiotherapy, S1, Xelox: 5-FU + radiotherapy, S1 and Xelox (HR = 0.75;
95% CI, 0.63–0.89; 0.63; 95% CI, 0.52–0.76; and 0.66; 95% CI, 0.51–0.85, respectively), with
no clear difference between adjuvants [105].
Some evidence in Asian populations (Resolve trial and Prodigy trial) supports the
role of perioperative treatment, although no Phase 3 trials have been published comparing
perioperative and adjuvant chemotherapy in stage II–III gastric cancer [106].
The completion rate of preoperative therapy in the above-mentioned Phase 3 studies
was approximately 90% [99–101]. This percentage drops dramatically when considering
preoperative and postoperative treatment (35–45%) [99–101]. In most recent adjuvant
trials with combination regimens, the percentage of patients completing treatment is
generally <70% [99–101]. In the SAKK 43/99 study comparing preoperative TCF (docetaxel,
cisplatin, and fluorouracil) with postoperative TCF, the percentage of patients completing
the four cycles was double in the preoperative therapy arm versus postoperative (75.8% vs.
37.5%) [107].
In MAGIC, the two treatment arms (perioperative chemotherapy and surgery) were
associated with similar postoperative complication rates (45.7% vs. 45.3%), with equal
mortality within 30 days of surgery (5.6% vs. 5.9%) and the same duration of recovery
(median: 13 days): only 10 patients did not start chemotherapy owing to postoperative
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complications [96]. Similar results have been reported in the French FNCLCC-FFCD [97].
Postoperative morbidity was 25.7% with chemotherapy compared with 19.1% with surgery,
with mortality rates of 4.6% and 4.5%, respectively.
A meta-analysis published in 2016 analyzed 11 studies in China and Japan, including
1240 patients with gastric cancer, demonstrating a survival advantage of perioperative
polychemotherapy compared with surgery followed by adjuvant chemotherapy (HR =
0.74; 95% CI, 0.61–0.89, p < 0.05) [108]. In a network meta-analysis including 4187 pa-
tients enrolled in 14 randomized studies, perioperative taxane-based polychemotherapy
improved survival compared with surgery alone (HR = 0.58; 95% CI, 0.38–0.91; p < 0.05)
and compared with surgery followed by adjuvant treatment (HR = 0.62; 95% CI, 0.42–0.93;
p < 0.05) [109]. In terms of adjuvant chemotherapy regimens, Xelox provided the best
survival benefit vs. other chemotherapy regimens: OS (HR = 0.47; 95% CI, 0.28–0.80) and
relapse-free survival (HR = 0.40; 95% CI, 0.24–0.64) [109].
In a subsequent network meta-analysis including 7235 patients, perioperative taxane-
based treatment with FLOT proved the most effective option for survival, followed by
adjuvant chemotherapy with platinum and 5-FU, and monotherapy with S1. In subsequent
subgroup analyses, chemotherapy with capecitabine and platinum proved to be the best
regimen in Asian populations, whereas chemotherapy with FLOT was better in European
populations [110].
Suggested approach in summarized in Figures 1–3.
Unanswered question: Is it time for a histotype-driven treatment?
Statement
The presence of SRCs at diagnosis does not change the indication of perioperative
treatment in patients with stage II or III gastric cancer.
Sources of Evidence
Lauren’s classification has identified two distinct subtypes based on histopathologic,
etiologic, biological, and prognostic characteristics: intestinal and diffuse (with or without
SRCs) [111]. Conversely, WHO classification defines five main histotypes: papillary, tubular,
mucinous, poorly cohesive, and mixed [112]. There is no evidence of a predictive role
for these different histotypes. A recent meta-analysis, including data from 73 published
studies of 61,000 patients, confirmed that patients with diffuse-type histotype have worse
prognosis compared with patients with intestinal subtypes (HR = 1.23; 95% CI, 1.17–1.29;
p < 0.0001) in loco-regional and advanced-stage disease (HR = 1.21; 95% CI, 1.12–1.30,
p < 0.0001 and HR = 1.25; 95% CI, 1.046–1.50; p = 0.014), regardless of any treatment added
to surgery [35].
In a French retrospective analysis of 924 patients with SRC neoplasia from 1997 to
2010, 171 patients received preoperative chemotherapy with cisplatin and 5-FU or cisplatin-
5-FU-epirubicin and 753 had upfront surgery [113]. Preoperative chemotherapy was
detrimental: median OS was 12.8 months versus 14.0 months in patients receiving only
surgery (p = 0.043) [113].
A subsequent German analysis confirmed the correlation between SRC component and
inadequate surgery (R1) associated with worse histopathologic response (<10% of residual
neoplasia in 16.3% vs. 28.9% of patients with intestinal histotype; p < 0.001) and increased
risk for peritoneal dissemination (p < 0.001) in patients with resectable gastric cancer treated
with preoperative chemotherapy (CF-based, with taxanes or epirubicin) [114].
In FLOT-4, the regression grade benefit observed with docetaxel (TRG = 1) was limited
to intestinal histotype (23% with FLOT and 10% with ECF/X) and not confirmed in diffuse
histotype (3% in both arms) [101]. Subsequent analysis of the SRC carcinoma group showed
that FLOT was effective in these patients (HR for survival: 0.74 vs. 0.79 in the intestinal
subgroup, log-rank p = 0.005). These data were confirmed by a French trial with TEFOX
(docetaxel, oxaliplatin, and 5-FU) in patients with locally advanced/unresectable and
metastatic gastric neoplasia [115]. In 65 patients with SRC carcinoma, objective response
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rate (ORR) was 66.1% and disease control rate (DCR) was 87.6% [107]. In this context,
data from the Phase 2 PRODIGE 19 study were reported at ASCO 2019: 83 patients
with SRC were randomized to upfront surgery followed by adjuvant chemotherapy or
perioperative ECF chemotherapy [116]. Resection rates and median survival were higher
with perioperative chemotherapy: R0, 88%/78%; 2-year OS, 60%/53.5%; median survival,
39/28 months (HR = 0.71; 95% CI, 0.40–2.64) [116].
All these data highlight the need for an intensive perioperative chemotherapy treat-
ment (if feasible, taxane-based) for patients with SRC carcinoma.
Unanswered question: Is there a role for molecular classification?
Statement
MSI status could be used for the selection of an appropriate therapeutic strategy:
specifically, perioperative chemotherapy versus upfront surgery.
Sources of Evidence
The TCGA research network analyzed the genomic profile of 295 gastric malignancies,
identifying four molecular subtypes of gastric cancer: neoplasms with MSI; neoplasms
related to EBV infection; neoplasia with chromosomal instability (CIN); and genomically
stable neoplasms (GS) [109]. The first group (22% of those analyzed) is characterized by
hypermethylation of CIMP or MLH1 and, together with the related EBV subtype (9%
of analyzed neoplasms) by the greatest benefit from immunotherapy. The CIN subtype
(50% of cases) is mainly characterized by tumors with an intestinal variant according to
Lauren classification and with gene alterations such as mutations involving in particular
TP53 [50]. Finally, the GS subtype seems to overlap the diffuse histotype according to
Lauren classification with alterations of CDH-1 and RHOA [50].
Currently, the molecular classification proposed by the TCGA research network, and
the subsequent classification proposed by Cristescu et al. [117] are only used in clinical
trials and not in clinical practice. The EBV subtype has the best prognosis, whereas patients
with the CIN subtype gain the greatest benefit from adjuvant chemotherapy (HR = 0.39;
95% CI, 0.16–0.94; p = 0.03), despite those with the GS subtype being characterized by poor
benefit from chemotherapy and the worst prognosis (HR vs. no chemotherapy 0.83; 95%
CI, 0.36–1.89; p = 0.65) [117–119].
MSI expression was more frequent in elderly patients with distal gastric carcinoma
and intestinal histotype according to Lauren, with a strong prognostic impact on stage
I-III gastric cancers [120,121]. These data were confirmed by a meta-analysis of 18,612
patients enrolled in 48 trials with an OS benefit reported with MSI (HR = 0.69; 95% CI,
0.56–0.86; p < 0.0001) [122]. Further, a subgroup analysis by Pietrantonio et al. using data
from MAGIC, CLASSIC, ITACA-S, and ARTIST trials highlighted the detrimental effect of
chemotherapy in patients with MSI: those with MSI-low/MSS gastric cancer benefitted
from chemotherapy with 5-year DFS of 57% compared with 41% in patients treated with
surgery alone (HR = 0.65; 95% CI, 0.53–0.79); 5-year OS was 62% versus 53% (HR = 0.75;
95% CI, 0.60–0.94) [123]. Conversely, those patients with MSI-high gastric cancer did not
benefit from chemotherapy: 5-year DFS, 70% versus 77% in the MSS group (HR = 1.27; 95%
CI, 0.53–3.04), and 5-year OS, 75% versus 83% (HR = 1.50; 95% CI, 0.55–4.12) [123]. The
effect of taxane-based chemotherapy (FLOT) is awaited. Role of MSI in localized disease is
summarized in Figures 1–3.
MSI status is also an important predictive tool in advanced disease: in a subgroup
analysis of KEYNOTE 059, 9 patients with MSI treated with pembrolizumab had an ORR
of 57.1% and DCR >70%, compared with an ORR of 9% and DCR of 22.2% in non-MSI-high
patients [53]. These results were confirmed in KEYNOTE 061 (ORR = 46.7%) and KEYNOTE
062 (ORR = 57%) and in a recent Phase 2 Korean study (ORR = 85.7% in MSI-high and
ORR = 100% in EBV patients) [54,124,125].
Unanswered question: What is the treatment of choice for stage IB gastric cancer
(T2N0M0)?
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Statement
(1) Perioperative chemotherapy can be considered first choice for patients with stage IB
gastric cancer after multidisciplinary discussion about the site of the primary tumor,
the characteristics of the patient (age, performance status [PS], comorbidities), and
the biology of the tumor (histotype, MSI).
Sources of Evidence
The choice of the appropriate treatment for patients presenting with stage IB tumor
(T2N0M0) is still controversial and requires multidisciplinary evaluation. Although Italian
Society of Medical Oncology guidelines recommend the use of perioperative treatment for
patients who have T3 and/or N+ tumors, ESMO and NCCN guidelines recommend the use
of a perioperative strategy as treatment of choice in patients with muscular invasion gastric
cancer (>T1) regardless of clinical lymph node involvement. These recommendations
are based on the results of the main Phase 3 trials in perioperative treatment (MAGIC,
ACCORD, and FLOT-4) [96,97,101]. Although MAGIC only enrolled patients from stage II
onwards and ACCORD did not report any subgroup analyses on stage at diagnosis, FLOT-
4 clearly demonstrated a survival benefit with perioperative strategy in all subgroups,
including patients with cT1/2 (16%) and cN- (21%) tumors [96,97,101].
In GEJ tumors, the CROSS trial demonstrated survival benefit of chemoradiotherapy
with carboplatin and paclitaxel in addition to surgery in all patient subgroups, including
cN0 patients (32% of the study population) [126]. However, this benefit derived mostly
from patients with squamous histology.
Unanswered question: When should adjuvant chemotherapy be started?
Statement
Completion of adjuvant treatment is critical to reducing risk for recurrence. Adjuvant
chemotherapy should be undertaken within 8 weeks of surgery. If treatment is delayed
toallow recovery of the patient for better compliance, this should still be considered within
12 weeks of surgery.
Sources of Evidence
The interval between surgery and adjuvant chemotherapy (time to adjuvant) in pa-
tients with gastric cancer can be influenced by the long postoperative course characterized
by post-surgical complications and by the need for proper re-feeding of patients, and a
number of studies have emphasized the importance of completing adjuvant treatment (as
part of a perioperative program or absence of preoperative chemotherapy) [127–130].
In the Italian ITACA-S trial, chemotherapy was stopped in 201 patients (18.8%),
whereas it was completed without decreasing drug dosages only in a quarter of patients:
discontinuation of treatment impacted DFS (HR = 0.74; 95% CI, 0.60–0.91; p = 0.004) and
OS (HR = 0.69; 95% CI, 0.55–0.86; p = 0.001) on multivariate analysis [127]. In the same
study, patients with an extended interval between surgery and adjuvant chemotherapy
reported benefits for DFS (HR = 0.95; 95% CI, 0.89–1.00; p = 0.05) and OS (HR = 0.91; 95% CI,
0.86–0.97; p = 0.004). These data were confirmed by a retrospective analysis of 7942 patients
in which three groups of patients undergoing adjuvant chemotherapy within 8 weeks
of surgery, 8–12 weeks after surgery, and >12 weeks after surgery had the same benefit
from adjuvant treatment [128]. In contrast, two subsequent Korean analyses showed that
prolonging the chemotherapy-free interval beyond 2 months in one study and over 28 days
in the second seems to have a detrimental effect on the risk of recurrence [129,130].
These studies were included in a meta-analysis by Petrelli et al.: initiation of adjuvant
treatment beyond 8 weeks after surgery was detrimental on survival (HR = 1.2; 95% CI,
1.04–1.38; p = 0.01) [131].
Unanswered question: When should adjuvant chemoradiotherapy be considered?
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Statements
(1) In patients with stage II/III gastric cancer undergoing suboptimal surgical (<D2) or
with R1, adjuvant chemoradiotherapy should be considered as the first therapeutic
option.
(2) In patients with stage II/III gastric cancer undergoing radical surgery, adjuvant
chemoradiotherapy can be considered after adjuvant chemotherapy in pN+ patients,
after multidisciplinary discussion.
Sources of Evidence
A randomized study published in 2001 (INT 0116) on 556 patients demonstrated a
survival benefit for patients treated with concomitant postoperative 5-FU chemoradiother-
apy compared with surgery alone [132]. The combined approach was superior both for
3-year DFS (48% vs. 31%; p < 0.001) and OS (50% vs. 41%; HR = 1.35; 95% CI, 1.09–1.66;
p = 0.05) [133]. These results were confirmed in the 10-year update. However, INT 0116
was criticized for the low quality of the surgery, evidenced by the low probability of sur-
vival and high percentage of local recurrences attributed to the very small number of D2
resections compared with the prevalence of D0 resections (D2, 10%; D1, 36%; D0, 54%). A
retrospective study published in 2005 of 544 Asian patients undergoing D2 resection fol-
lowed by chemoradiotherapy had a 20% mortality reduction (HR = 0.80; p = 0.02) compared
with a group of 446 undergoing D2 resection in the same period [134].
The role of adjuvant chemoradiotherapy in radical resected patients was evaluated in
ARTIST: patients who underwent D2 resection received chemotherapy with CDDP and
capecitabine for six cycles or two cycles of the same chemotherapy followed by concomitant
chemoradiotherapy [135]. With a median follow-up of 53.2 months, there was no significant
advantage of DFS with chemoradiotherapy compared with chemotherapy (78.2% vs. 74.2%;
p < 0.086). These results were confirmed by an analysis in the IB subgroup (according to
AJCC 2002) [136]. However, DFS was superior to chemoradiotherapy in the pN+ subgroup
(77.5% vs. 72.3%; p = 0.036). Further, in the latest update of the study, there was a significant
benefit for locoregional recurrences in the chemoradiotherapy arm (7% vs. 13%; p = 0.03),
that was more marked for the pN+ subgroup (p = 0.009) [137].
This result led the group to undertake ARTIST 2, aimed at testing the role of chemora-
diotherapy only in pN+ patients undergoing D2 resection. In an interim analysis there was
no reduction in risk of recurrence from the addition of radiotherapy to polychemotherapy
with S1 and oxaliplatin (HR = 0.910; p = 0.667) [138].
3.5.4. Treatment of Siewert II Adenocarcinoma
Unanswered question: Should perioperative chemotherapy or preoperative chemora-
diotherapy be the preferred option in patients with Siewert II adenocarcinoma?
Statement
(1) In patients with Siewert II adenocarcinoma, while acknowledging the fundamen-
tal role of a multidisciplinary discussion for every single situation, perioperative
chemotherapy with FLOT is preferable, reserving preoperative chemoradiotherapy
for patients at high risk for R1 resection and local recurrence.
Sources of Evidence
Two studies have compared chemoradiotherapy and preoperative chemotherapy
in patients with GEJ adenocarcinoma, although both closed early owing to poor enroll-
ment [139,140]. In the first, patients were randomized to receive cisplatin and 5-FU chemora-
diotherapy (39 patients) or chemotherapy alone (36 patients) [137]. Median OS was 32
versus 29 months (p = 0.83) but significant regression was documented in the combination
arm (pathologic complete response [pCR]: 13% vs. 0%; p = 0.02) [140]. POET randomized
126 patients to chemoradiotherapy or chemotherapy alone, with a survival benefit at 3 and
5 years in the first group (46.7% and 39.5% vs. 26.1% and 24.4%, respectively) at the expense
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of increased postoperative mortality (10.2% vs. 3.8%; p = 0.26) [139]. Thus, there was a
trend for OS in favor of preoperative chemoradiotherapy (HR = 0.65; 95% CI, 0.42–1.01;
p = 0.055). The advantage of the combination was also confirmed for pCR (15.6% vs. 2.0%;
p = 0.03), R0 resection rates (15.4% vs. 4.1%), and pCR at lymph node level (pN0, 64% vs.
38.8%; p < 0.001).
In a meta-analysis of 22 studies and 18,260 patients, the benefit of preoperative
chemoradiotherapy compared with chemotherapy alone was evident only in pCR rate
(odds ratio [OR] = 2.8 in favor of combined treatment; 95% CI, 2.27–3.47; p < 0.001) and
reduction of local recurrence (OR = 0.6; 95% CI, 0.39–0.91; p = 0.01) with no benefit in
distant relapses or survival [141].
In CROSS, survival benefit at 5 years from addition of preoperative chemoradiother-
apy to surgery in the entire cohort (squamous cell carcinoma and adenocarcinoma) was
14% [126]. Of the 366 patients enrolled, 88 had gastroesophageal Siewert I-II adenocarci-
noma: in this group of patients, median OS increased from 27.1 months to 43.2 months [126].
In FLOT-4, approximately 56% of patients enrolled had a GEJ malignancy (Siewert I–
III); the OS benefit in the study (5-year survival increased by 9% with FLOT vs. ECF/ECX)
was also observed in the subgroup of patients with pCR, with results comparable to
preoperative chemoradiotherapy treatment (16% in FLOT-4 vs. 14% in POET) [101].
Neo-AEGIS and ESOPEC are currently enrolling patients with adenocarcinoma of the
esophageal/GEJ to perioperative treatment with ECF (Neo-AGIS) or FLOT (ESOPEC) or
neoadjuvant chemoradiotherapy according to CROSS scheme.
3.6. Treatment of Elderly Patients with Locally Advanced Resectable Disease
3.6.1. (Neo-)Adjuvant Therapy
Unanswered questions: Does age influence treatment choice in locally advanced
resectable disease? Is there a role for multidimensional geriatric assessment (MGA)?
Statements
1. MGA allows the identification of frail patients who are at higher risk for complications
after gastrectomy.
2. The role of MGA in determining medical treatment is less established in resectable
disease compared with the palliative setting. However, MGA might also help the
MDT in personalizing treatment approaches when the aim of treatment is curative.
3. Age does not impact perioperative chemotherapy benefit over surgery alone or the
benefit of FLOT over ECF/ECX.
4. High-grade toxicities with FLOT are more common in the elderly. Accurate patient
selection is therefore needed with taxane-based triplet regimens.
Sources of Evidence
Both MAGIC and FLOT-4 defined elderly patients as those 70 years or older [93,121].
A significant proportion of elderly patients have been enrolled in each study (20.4% and
24%, respectively). There is no significant interaction between treatment effect for the
experimental arm and age in these studies, with HRs favoring experimental treatment
in this subset. Indeed, in locally advanced and metastatic disease, the FLOT65+ study
reported a higher incidence of grade 3-4 toxicities with FLOT compared with FLO [137].
MGA is an important instrument in the palliative setting, useful for identifying frail
patients at higher risk of toxicity and rapid deterioration [139,140]. Studies investigating
MGA in locally advanced resectable disease as a tool to inform medical (neo-)adjuvant
treatment are lacking. Evidence of frailty at MGA is associated with increased risk for
postoperative complications and readmission within 1 year of resection [142,143].
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3.6.2. Treatment of Locally Advanced Unresectable and Metastatic Disease
First-Line Therapy
Unanswered questions: Is there a preferred first-line regimen in advanced gastric
cancer? Which clinical parameters (e.g., PS, comorbidities, previous treatments, age) should
be considered in the definition of optimal first-line therapy? What are the main biological
parameters (e.g., HER2 and MSI status, EBV+, PDL-1 expression) when defining optimal
first-line therapy? How should the aim of treatment guide treatment choice in first line?
Is it possible to define oligometastatic disease? Which of the following elements should
be considered in the treatment of advanced disease: rebiopsy on sites of recurrence, re-
assessment of HER2 status on sites of recurrence, or liquid biopsy to guide treatment choice
and monitor treatment efficacy?
Statements
(1) Patient PS, comorbidities, and disease burden are all factors that should be considered
in the choice of first-line therapy.
(2) Among molecular parameters investigated, only HER2 status has been validated as a
predictive biomarker for choice of first-line therapy.
(3) Platinum plus fluoropyrimidine doublet chemotherapy regimens represent standard
of care in this setting.
(4) Triplet chemotherapy, mainly FLOT, is preferable for selected fit patients (i.e., with
Eastern Cooperative Oncology Group [ECOG] PS 0–1, adequate organ function) with
either locally advanced unresectable disease or high tumor burden.
(5) While deciding optimal first-line chemotherapy in individual patients, a cautious
assessment of residual toxicity from (neo-)adjuvant therapies as well as time interval
between treatment interruption and evidence of recurrence is recommended.
(6) For fit patients experiencing progression soon after (i.e., ≤6 months of completion) or
during adjuvant treatment with platinum plus fluoropyrimidine, the combination of
paclitaxel plus ramucirumab is the preferred choice.
(7) For fit patients experiencing progression soon after (i.e., ≤6 months of completion)
or during adjuvant treatment with docetaxel, FOLFIRI or ramucirumab should be
considered. If recurrence occurs >6 months after completion of adjuvant therapy,
paclitaxel plus ramucirumab should be considered.
Sources of Evidence
Several meta-analyses have evaluated the optimal first-line chemotherapy regimen
in advanced gastric cancer. Wagner et al. analyzed 64 trials comparing different first-
line chemotherapy regimens with an active comparator or best supportive care (BSC)
alone [144]. Chemotherapy significantly prolonged OS compared with BSC, and combina-
tion chemotherapy was superior to single-agent chemotherapy, although the advantage of
polychemotherapy was modest. A subsequent network meta-analysis tried to determine
the preferred first-line regimen among different options available [145]: fluoropyrimidine-
based doublets with oxaliplatin, irinotecan, or docetaxel were preferred on the basis of
survival and safety profiles, whereas FLOT was the most effective and well tolerated triplet
compared with conventional doublets. These findings were confirmed in a subsequent
conventional meta-analysis of three versus two agents, which confirmed that three-drug
regimens containing fluoropyrimidines (vs. no fluoropyrimidines), cisplatin (vs. no cis-
platin), and docetaxel (vs. no docetaxel) were associated with a significant OS advantage
over doublets [146].
Chau et al. first investigated the main clinical prognostic determinants in 1080 patients
with advanced esophagogastric cancer from three randomized, controlled trials [147]. Four
poor prognosis parameters were identified: PS > 2, liver metastases, peritoneal carcino-
matosis, and baseline alkaline phosphatase >100 U/L. Scores based on these variables
stratified patients into three risk categories: low (no risk factors), moderate (1–2 risk fac-
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tors), and high (3–4 risk factors), associated with significantly different OS. The same group
subsequently validated the prognostic score on the separate REAL-2 database [148].
Similar analyses have also been conducted using data from patients not included in
randomized, controlled trials [149,150]. PS, peritoneal metastases, and alkaline phosphatase
were confirmed as poor prognostic determinants [149,150]. Wang et al. developed a
prognostic score comprising presence of on-site primary tumor, number of disease sites,
bone or liver metastases, and neutrophil-to-lymphocyte ratio [150]. Again, the score
identified three risk groups with significantly different OS.
None of these studies investigated the role of age. As more effective and intensive
doublet and triplet regimens are used, an increased interest has been focused on elderly
patients, to establish tolerability and efficacy of modern combinations in this underrepre-
sented population in clinical trials. Age has been found as a main determinant of treatment
choices in routine clinical practice [151]. In FLOT65+ [152], FLOT was associated with
higher relative risk (RR) than 5-FU plus oxaliplatin, but grade 3/4 toxicity also increased
in patients aged ≥65 years. In particular, triplet was associated with higher rates of neu-
tropenia, leucopenia, diarrhea, and nausea. A subset analysis did not confirm the benefit
of triplet among patients >70 years.
No definitive data are available on first-line treatment choice after a (neo-)adjuvant
regimen. This is partly due to the high proportion of patients with synchronous distant
metastases or unresectable disease at diagnosis and the rapid deterioration in many pa-
tients after recurrence [153]. Even if confirmation from prospective data is lacking, disease
progression after ≥6 months of completion of (neo-)adjuvant systemic therapy (generally
comprising a platinum derivative and fluoropyrimidine) is generally regarded as an ade-
quate period to also consider the same agents in first line [154–156]. The main challenge is
represented by those patients progressing within 6 months of completion of adjuvant ther-
apies: in such cases, disease can be considered refractory to the agents used in the curative
setting, and second-line therapy is considered adequate. In RAINBOW, 76% of patients en-
rolled experienced disease progression within 6 months of fluoropyrimidine plus platinum
(69% received this treatment as first-line) [157]. The benefit of paclitaxel plus ramucirumab
was also confirmed in the subset of patients with progression-free survival (PFS) <6 months
in the previous line, which also included patients progressing during adjuvant treatment.
Therefore, in early progression after platinum plus fluoropyrimidine, paclitaxel plus ramu-
cirumab may be considered a preferred option. If progression occurs during or early after
perioperative FLOT, even with the lack of adequate literature, irinotecan (either alone or
with 5-FU) [158] or ramucirumab monotherapy (particularly for patients with initial PS
deterioration) can be considered [159]. First-line 5-fluorouracil plus irinotecan (FOLFIRI) is
among the accepted doublets in randomized trials and meta-analyses [160]: therefore, this
regimen should be considered, particularly in patients with residual toxicity from adjuvant
therapies (e.g., peripheral neurotoxicity), which may impact QoL.
Trastuzumab is the only approved targeted first-line agent. Its label was updated
based on the results of the Phase 3 ToGA trial [46], which demonstrated that adding
trastuzumab to first-line cisplatin plus fluoropyrimidine resulted in increased OS, PFS, time
to progression (TTP), and RR compared with placebo. Based on these data, trastuzumab
is now standard-of-care in combination with platinum plus fluoropyrimidine doublet for
patients with HER2-positive disease, defined as HER2 3+ or HER2 2+ at IHC with gene
amplification by FISH.
First-line treatment options are summarized in Figure 4.
Other than HER2 status, no other molecular biomarker has entered clinical practice.
KEYNOTE-062 demonstrated that pembrolizumab monotherapy is non-inferior to first-
line chemotherapy for OS in patients with PDL-1-positive disease (defined as CPS ≥1),
whereas adding pembrolizumab to chemotherapy did not result in increased OS [54]. In
a subgroup analysis of patients with PDL-1 CPS ≥10, single-agent pembrolizumab was
superior to chemotherapy for OS. KEYNOTE-062 results are consistent with KEYNOTE-
061 and KEYNOTE-059 [53,119], and support further research into PDL-1 as potential
Cancers 2021, 13, 1304 21 of 41
biomarker for pembrolizumab efficacy. KEYNOTE-062 exploratory analyses into the
role of MSI status clearly show that patients with MSI-high disease derive the greatest
benefit from pembrolizumab, both as single agent and in combination with chemotherapy.
Future studies will clarify the role of MSI and EBV status in determining benefits of
immunotherapy, as these parameters seem the most promising predictive biomarkers for
anti-PD(L)1 agents [118].
The need for HER2 reassessment at recurrence is a matter of research, but is not
mandatory in routine practice [156].
HER2 expression is heterogeneous in gastric cancer [161] and this feature might also
impact treatment efficacy with anti-HER2 agents [162]. However, availability of surgical
tissue from previous gastrectomy should increase the accuracy in HER2 evaluation com-
pared with limited biopsy samples [163,164]. Therefore, HER2 assessment on surgical
samples (if already available) is regarded as adequate to select candidates for trastuzumab.
For patients with synchronous distant metastases, biopsy of both primary tumor and
metastatic sites are acceptable for HER2 evaluation, provided all quality requirements for
pathologic and molecular assessment are met. Some series have highlighted the possibil-
ity of discordant results between primary tumor and metastasis HER2 expression. The
GASTHER-1 prospective study found that rescued HER2-positivity rate of 8.7% could be
recognized with additional sampling among patients whose tumor was initially defined as
HER2-negative, particularly among tumors with non-diffuse histology and HER2 2+ [165].
Moreover, a HER2-positivity rate of 5.7% was recognized by sampling of metastases in
initially HER2-negative patients; this was associated with metastatic site (liver lesions
being more frequently HER2-positive). Notably, patients with rescued HER2-positive
tumors seem to derive similar benefits from first-line trastuzumab compared with initially
HER2-positive patients. Other series have confirmed the high concordance rate between
HER2-status assessment on primary tumor and matched metastases [166].
Some preliminary reports have been published on the possible role of liquid biopsy for
HER2 evaluation on circulating tumor DNA [167]. As in other malignancies, it is possible
that this technique will help in monitoring treatment response during anti-HER2 therapy
rather than substitute tissue assessment for HER2 evaluation.
Advanced gastric cancer comprises different clinical situations. Yoshida et al. classi-
fied stage IV disease into four subgroups based on sites involved and extent of involve-
ment [168]. In their opinion, this could guide conversion surgery in patients benefiting
from chemotherapy. Historically, two main subsets of patients have been defined: those
with locally advanced unresectable disease (mainly due to primary tumor extension and/or
abdominal nodal involvement) and those with distant metastatic disease [169]. Although of-
ten combined and treated as a single entity, the prognosis differs, and different approaches
can be considered in these two groups. Although first-line chemotherapy is the mainstay
of treatment in both cases, more intensive triplet schedule may be justified in patients
with locally advanced disease, where conversion to respectability is a reasonable goal of
treatment [170]. Recently, surgical strategies have been extended in selected gastric cancer
patients beyond nodal involvement, to pulmonary metastases [171], liver metastases [172],
and even peritoneal involvement [173]. FLOT-3 explored the role of FLOT in different
patient subsets, such as those with oligometastatic disease reconsidered for surgery after
response [174]. Among these patients effectively submitted to surgery, interesting OS
results have been reported, thus supporting the ongoing randomized trial conducted by
the German AIO Group RENAISSANCE/FLOT5 (NCT02578368).
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Second-Line Therapy
Unanswered questions: Regarding patient characteristics, which are the main drivers
in second-line treatment decision? Is paclitaxel plus ramucirumab the standard second-line
therapy after docetaxel-based first-line or (neo-)adjuvant therapy?
Statements
(1) Considering the aggressiveness of the disease, often associated with rapid deteriora-
tion, many patients do not receive second-line therapy (in Western countries, ~30–40%
of patients receive salvage therapies).
(2) To increase the number of patients who are candidates for second-line therapies,
accurate patient monitoring during first-line therapy is mandatory, to capture early
signs of clinical progression which may anticipate radiographic progression.
(3) Imaging for disease assessment should ideally be performed every 2 months in
patients with metastatic disease and should be accompanied by detailed and close
monitoring of clinical conditions.
(4) All patients with ECOG PS 0 or 1 should be offered second-line treatment after
progression to first-line therapy.
(5) ECOG PS ≥ 2 patients are candidates for BSC alone.
(6) For patients with gastric or GEJ cancer that has progressed after first-line therapy not
including a taxane, the combination of paclitaxel and ramucirumab is the preferred
choice.
(7) For patients with gastric or GEJ cancer that has progressed after first-line therapy
with a taxane, the combination of paclitaxel and ramucirumab should be consid-
ered in patients with previous response to first-line therapy. In all other patients,
including those with contraindications to this combination, alternative options can be
considered, such as single-agent ramucirumab or irinotecan.
Sources of Evidence
Approximately 35–40% of Western patients and up to 75% of Eastern patients are
treated with second-line therapies [153]. Randomized studies and meta-analyses confirm
that active treatment improves OS and QoL compared with BSC alone [158,175]. Currently,
second-line treatment options do not differ according to HER2 status—recent trials did not
suggest any benefit from trastuzumab beyond progression in HER2-positive gastric cancer
treated with trastuzumab in first line [176]. Among cytotoxic agents, irinotecan, docetaxel,
and paclitaxel are all effective agents, supported by randomized trials. In particular, the
COUGAR-2 study demonstrated an OS benefit for docetaxel over BSC alone [177], whereas
irinotecan (initially found effective over BSC in a small randomized trial [178]) was proved
equally effective to paclitaxel (with paclitaxel associated with a more favorable safety
profile) in WJOG 4007 [179] and KSCG ST10-01 [180].
Among biologic agents, only the anti-VEGFR2 antibody ramucirumab demonstrated
prolonged OS compared with BSC as single-agent [159] or when tested in combination
with paclitaxel against paclitaxel alone [157]. Real-life data confirmed the efficacy of
ramucirumab in routine practice [181].
No validated predictive parameters exist to definitively identify patients who will
benefit most from palliative chemotherapy or ramucirumab [182]. Therefore, clinical
selection remains essential to maximize the benefit of salvage therapies while minimizing
the risk for futile toxicity. Several clinical variables are associated with OS in second
line. PS is one of the main determinants of patient outcome in most series (ECOG PS ≥ 2
being almost invariably associated with dismal prognosis and representing an exclusion
criterion for randomized trials) and should therefore guide treatment allocation [183,184].
Other parameters can also be used, such as benefit (for PFS) from first-line, neutrophil-to-
lymphocyte ratio, lactate dehydrogenase values, and hemoglobin levels [185]. However,
external validation for these variables is lacking and they cannot be currently used to
deny active treatment in individual patients but may be useful in better stratifying patient
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prognosis after first progression [186]. Notably, age per se does not influence the efficacy of
ramucirumab and chemotherapy in second line [183,187].
A second-line therapy should be offered to all patients with preserved general con-
ditions (ECOG PS 0–1) after progression to first-line [156]. As for initial therapy, patient
comorbidities as well as residual toxicities and benefit from previous systemic treatments
could inform the choice of optimal agent or regimen to be used in second line. Pacli-
taxel plus ramucirumab is the only combination to demonstrate an OS advantage over
single-agent chemotherapy in a randomized study [157]. Therefore, it is now regarded
as standard of care in fit patients in second line, whereas monotherapy with docetaxel,
paclitaxel, irinotecan, or ramucirumab is generally reserved for patients judged unsuitable
for combination treatment [154–156]. For patients benefiting from first-line therapy in
terms of response and PFS (progressing ≥3–4 months after first-line therapy), retreatment
with first-line agents is also an option, but cumulative toxicity should be closely monitored
before and during treatment and the possibility of offering salvage agents in case of rapid
progression carefully evaluated in single cases. BSC remains preferable in patients with
deteriorated conditions (ECOG PS ≥ 2) [154–156].
In RAINBOW, patients already treated with a taxane were excluded [157]. This makes
it difficult to draw conclusions on the efficacy of paclitaxel plus ramucirumab after a
first-line triplet regimen such as FLOT (or in patients with early progression after adjuvant
FLOT). In RAMIRIS (AIO-STO-0415), a randomized Phase 2 study investigating the role of
FOLFIRI plus ramucirumab compared with paclitaxel plus ramucirumab in second line,
among docetaxel-pretreated patients, PFS with FOLFIRI was superior to paclitaxel when
combined with ramucirumab, supporting the ongoing Phase 3 trial [188,189]. However,
taking into account licensed indications for each country, the combination of paclitaxel plus
ramucirumab should also be considered for docetaxel-pretreated patients with previous
response to taxane-based therapy.
Second-line treatment alternatives are summarized in Figure 5.
3.6.3. Role of Maintenance Therapy After First- and Second-Line Treatment
Unanswered questions: What is the optimal duration of first- and second-line treat-
ment? Is there a role for maintenance therapy? Which is the optimal maintenance therapy?
Does HER2 status impact maintenance therapy selection?
Statements
1. Optimal treatment duration in first or second line cannot be informed by literature
evidence and should be tailored to individual patient preference and tolerance.
2. The choice of shifting to maintenance treatment should be individualized after dis-
cussion with the patient about the risk-to-benefit ratio of this approach.
3. After 6 months of first-line combination treatment without evidence of progression,
patients with HER2-positive disease can be offered maintenance with trastuzumab,
either as single-agent or combined with fluoropyrimidine.
4. Maintenance with ramucirumab monotherapy can be considered in patients treated
with second-line paclitaxel plus ramucirumab with unacceptable toxicities related to
paclitaxel.
Sources of Evidence
No clear indication is yet available from the literature about the optimal treatment
duration in first or second line. Randomized trials generally continued treatment until
disease progression.
Maintenance therapy is generally offered in advanced cancer cases to prolong TTP,
while preserving QoL in patients already treated with combination therapy upfront [190].
In metastatic gastroesophageal cancer, the role of such an approach is still controversial.
Single-agent fluoropyrimidines have been most extensively investigated for this use; in
particular, maintenance capecitabine after six cycles of XELOX prolonged PFS compared
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with observation alone [191]. Several smaller, uncontrolled studies confirmed these find-
ings [192,193].
Based on data available for first-line chemotherapy (showing median PFS results for
doublet or triplet rarely exceeding 6 months) and the toxicity profile of the agents most
used in first-line (with the risks of cumulative toxicity for platinum compounds or taxanes),
patients achieving disease control after 6 months of combination therapy are candidates for
fluoropyrimidine maintenance until unacceptable toxicity, evidence of disease progression,
or patient refusal [191–193] (Figure 4).
No evidence exists on the role of maintenance for second-line therapy. RAINBOW
showed that ramucirumab can be maintained until unacceptable toxicity, evidence of
disease progression, or patient refusal due to paclitaxel-related toxicities [157].
In patients with HER2-positive disease receiving combination chemotherapy plus
trastuzumab, the anti-HER2 antibody should be maintained, with or without fluoropyrimi-
dine, and continued until progression if accepted and tolerated, as scheduled in ToGA [46].
This strategy has proved well-tolerated and is accepted as the best approach to maximize
the benefit of induction first-line therapy.
In HER2-negative disease, fluoropyrimidines represent the only maintenance ther-
apy option. Ongoing randomized trials such as ARMANI [194] and MATEO [195] will
clarify the role of different maintenance approaches (paclitaxel plus ramucirumab and S1,
respectively) after a scheduled period of induction doublet chemotherapy.
3.6.4. Role of Third-Line Therapy
Unanswered questions: Should a third-line treatment be offered in routine practice?
Statements
1. Fewer than 20% of Western gastric cancer patients are offered third-line therapies in
clinical practice.
2. Patients with adequate general health (ECOG PS 0–1) who experience progression
on second-line therapy may be considered for third-line therapies. Among cytotoxic
agents, TAS102 (if available) is a preferred option; irinotecan (if not used in previous
lines) may be considered if TAS102 is not available.
Sources of Evidence
Randomized trials suggest that 10–20% of patients treated for advanced disease receive
third-line systemic therapy [153]. This percentage may be higher in Eastern countries,
where 30–40% of selected patients included in randomized trials receive salvage therapies
beyond second line [153]. Recent real-world data confirm these percentages and provide
evidence of a modest benefit from cytotoxic agents not used in earlier lines [196,197].
Recently, TAS102 has been compared with placebo after two lines of therapy in a
randomized Phase 3 trial [198]. TAS102 was significantly superior to placebo in terms of
OS and reported a trend towards reducing the risk of QoL deterioration compared with
placebo [199].
3.6.5. Role of Immunotherapy in Advanced Disease
Unanswered questions: Is there a role for ICIs in metastatic gastroesophageal cancer?
Is there any predictive biomarker for ICIs in metastatic gastroesophageal cancer? What is
the cost-to-benefit ratio of ICIs?
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Statements
1. For patients with MSI-high disease, treatment with immune checkpoint inhibitors
(ICIs) should be considered if not administered in earlier lines.
2. Based on already published or presented Phase 3 studies investigating ICIs either
alone or in combination with chemotherapy, ICIs should not be offered in routine
practice to unselected metastatic gastric cancer patients outside clinical trials.
3. Based on available efficacy data of ICIs in MSI-high gastric cancer patients, treatment
with ICIs should always be considered in this subgroup within clinical trials or as
off-label use.
4. No pharmacoeconomic analyses have been published on the use of ICIs in advanced
disease.
Sources of Evidence
Several trials have evaluated ICIs in metastatic gastroesophageal cancer. As first-line
therapy, KEYNOTE-062 compared chemotherapy alone (cisplatin plus 5-FU or capecitabine)
with chemotherapy plus pembrolizumab or pembrolizumab alone among patients with
HER2-negative, PD-L1 CPS-positive disease [54]. The primary endpoints were OS in
CPS ≥1 and ≥10 for pembrolizumab plus chemotherapy versus chemotherapy and pem-
brolizumab versus chemotherapy, as well as PFS in CPS ≥1 for pembrolizumab plus
chemotherapy versus chemotherapy. Pembrolizumab monotherapy was non-inferior
to chemotherapy but was associated with favorable safety. Adding pembrolizumab to
chemotherapy did not significantly improve OS [54]. An exploratory analysis of >50 pa-
tients with MSI-high tumor showed superior RR, PFS, and OS in both pembrolizumab
arms over chemotherapy alone, demonstrating that this subgroup may achieve particularly
improved outcomes with pembrolizumab [200].
Another trial assessed avelumab versus continued chemotherapy as maintenance
after 12 weeks’ induction oxaliplatin plus fluoropyrimidine therapy [201]. Avelumab failed
to meet the primary endpoint of improving OS after induction, either in all randomized
patients or the PD-L1+ subgroup (≥1% of tumor cells).
Among pretreated patients, three Phase 3 trials have been published. The ATTRACTION-
2 study assessed nivolumab in patients treated with at least 2 lines of systemic therapy [202].
Nivolumab improved RR, PFS, and OS without unexpected toxicity [202]; the benefit
was independent of PD-L1 status according to a post-hoc analysis in >39% of enrolled
patients [202]. JAVELIN GASTRIC 300 evaluated avelumab as third-line therapy [203].
Compared with investigator’s choice chemotherapy, avelumab did not demonstrate any
superiority in RR, PFS, and OS, even after patient stratification according to PD-L1 status.
Finally, KEYNOTE-061 study compared pembrolizumab with paclitaxel as second-line
therapy for patients with PD-L1 CPS ≥1% [119]. Pembrolizumab did not improve OS
over paclitaxel and was associated with a shorter PFS and similar RR compared with
chemotherapy.
Based on these results, no ICI is currently approved by European Medicines Agency
(EMA) for metastatic esophagogastric cancer.
Factors that have been investigated most as potential predictive biomarkers for ICIs
in this disease are:
PD-L1 expression assessed as either CPS or tumor-positive score: increased PD-L1
expression is generally associated with increased benefit from ICIs, namely pembrolizumab
for PD-L1 CPS [54,119]. However, no external validity of this biomarker has been demon-
strated with different ICIs [202,203].
MSI status: post-hoc analyses of randomized trials and Phase 2 studies confirm high
activity and sustained efficacy of ICIs in this subgroup [118,204,205]. In randomized
trials, investigational ICIs seem better than standard treatments in patients with MSI-high
disease [119,200] (Figures 4 and 5).
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EBV status: EBV-positive and MSI-high patients harbor a greater immune infiltrate
and higher PD-L1 expression [206]. Limited series are available, but data seem reassuring
about the sensitivity of EBV-positive gastric cancer to ICIs [118,207].
No pharmacoeconomic analyses have yet been published. Moreover, conflicting
data about the efficacy of different ICIs in different settings and patient populations, as
well as mechanisms of reimbursement in different countries, preclude drawing definitive
conclusions.
Data suggest that the toxicity profile of ICIs in gastric cancer is similar to that ob-
served in other malignancies, and combining anti-PD-1 agents with chemotherapy is feasi-
ble [200]. QoL analysis for first-line therapy in KEYNOTE-062 showed similar outcomes
for pembrolizumab compared with chemotherapy, but the toxicity profile of single-agent
pembrolizumab is generally milder [208].
3.6.6. Role of HIPEC and PIPAC in Advanced Disease
Unanswered questions: What is the role of hyperthermic intraperitoneal chemother-
apy (HIPEC) and pressurized intraperitoneal aerosol chemotherapy (PIPAC), if any, in
gastric cancer?
Statements
(1) Results for CRS plus HIPEC in gastric cancer with peritoneal involvement are limited
and controversial. While confirmation in randomized trials is ongoing, this approach
should be offered only within a clinical trial.
(2) There is currently insufficient evidence to recommend the use of PIPAC outside
a clinical trial. The use of this technique may be of particular interest in treating
uncontrolled malignant ascites.
Sources of Evidence
The use of cytoreductive surgery (CRS) plus HIPEC or PIPAC in gastric cancer is
confined to clinical trials [209]. Available studies are generally not controlled, populations
are heterogeneous, and results for OS conflicting [210]. These limitations do not permit the
identification of optimal candidates for the procedures or for a comparison with systemic
treatment alone in for OS and QoL. Although these procedures are generally performed
in high-volume centers, complications are frequently reported, especially with HIPEC.
Ongoing randomized trials will clarify the role of intraperitoneal therapies, as current
evidence suggests the potentials of HIPEC to prolong OS [211].
3.6.7. Nutritional Support During Treatment of Advanced Disease
Unanswered questions: What is the role of home parenteral nutrition (HPN) in
metastatic gastric cancer?
Statement
(1) HPN is a valid therapeutic option for malnourished patients with advanced gastric
cancer. To reduce the risks related to HPN, this approach should be planned and
managed by dedicated personnel according to validated protocols.
Sources of Evidence
HPN is indicated in patients with alterations in the gastrointestinal tract precluding
adequate oral caloric intake (i.e., with oral intake of <60% of required for prolonged peri-
ods) [212,213]. Parenteral nutrition is effective in improving nutritional status, QoL, and, in
selected patients with advanced gastric cancer, OS [214–216]. Malnutrition, sarcopenia, and
cachexia are poor prognostic determinants in this setting [14]. However, HPN is associated
with risks of glycemic decompensation and central venous catheter infections [217], and
therefore dedicated personnel within the nutritional support team should be responsible
for prescribing and monitoring HPN.
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Unanswered questions: What is the preferred timing of nutritional support, upfront
versus when needed?
Statements
(1) Nutritional status assessment must be performed before treatment initiation in all
patients who are candidates for systemic therapies.
(2) Nutritional support need and programming of such support should be established by
a dedicated nutrition expert.
Sources of Evidence
Up to 80% of patients with advanced esophagogastric cancer present with malnutrition.
Sarcopenia is also a risk factor for increased toxicity of systemic chemotherapy [14,15].
Cytotoxic agents are generally dosed according to body surface area (BSA), which does
not account for differences in body composition, thus possibly impacting drug exposure
in patients with similar BSAs. Moreover, chemotherapy may further impact lean body
mass loss, further worsening sarcopenia in some patients [218]. Therefore, assessment
of nutritional status should be part of the clinical assessment on diagnosis of advanced
disease, and evaluation by a nutrition expert should be offered before treatment initiation
to all malnourished patients or those at risk of malnutrition.
Enteral or parenteral nutritional support in these patients is indicated to improve body
weight, allow treatment administration as scheduled, and recover from gastrointestinal
toxicity of treatments. In terminal phases, nutritional support appears to be less effective,
and potential risks may overwhelm benefits [212].
Studies confirm that the success of nutritional support lies on the involvement of a
dedicated nutrition expert in the full course of treatment [212].
3.6.8. Definition of a Continuum of Care in Advanced Gastric Cancer
Unanswered questions: What is the impact of centralization of medical treatment in
advanced gastric cancer?
Statement
(1) Multidisciplinary management, rather than treatment centralization in high-volume
centers, represents the most effective strategy to optimize the continuum of care of
medical therapies in all treatment phases.
Sources of Evidence
In advanced gastroesophageal cancer, the impact of the number of patients on outcome
of palliative medical therapies has not been fully evaluated. A recent Dutch registry study
reported a significant, if limited, advantage in OS for patients treated in high-volume
centers for medical and surgical therapies [219]. However, several factors should be
considered, such as more accurate selection of fit patients in referral centers, earlier and
more intensive supportive treatment, and available staff resource. On the other hand, the
hospital volume was not documented to have an impact on the surgical and oncological
outcomes in gastric cancer patients treated in East Asia [220].
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Figure 2. Treatment options for fit patients with resectable gastric or gastroesophageal junction adeno-
carcinoma already treated with preoperative therapy and surgery. FLOT, 5-fluorouracil/leucovorin,
oxaliplatin, and docetaxel; MSI, microsatellite instability.
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a high rate of agreement has been reached for most statements, suggesting that a shared
approach could be defined in most cases, even when conclusive evidence from literature
is lacking.
A potential limitation of the current project is represented by the involvement of
experts from high-volume centers across Italy, as this may have reduced the divergence
among the panelists. However, we tried to move in those areas of uncertainties not exhaus-
tively covered by literature data. Therefore, the general agreement that a multidisciplinary
approach is mandatory in any patient with a new diagnosis of gastric or GEJ cancer and
should be encouraged in any phase after the assessment of the results of different treatment
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